Physician profile
Raymond E Bruno
NPI 1023182888
$2,538.70
in general payments reported to CMS, 2019-2025
29 companies · $600 in 2025
The $600 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $345 · 2022: $321 · 2023: $687 · 2024: $586 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $468.32 | 2021-2025 | Breztri, Airsupra, Bevespi Aerosphere |
| Novo Nordisk INC | $323.58 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $307.41 | 2021-2024 | Otezla, Repatha, Evenity |
| Regeneron Healthcare Solutions, INC. | $163.96 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $129.57 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $108.32 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.71 | 2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $74.31 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Novartis Pharmaceuticals Corporation | $74.22 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $72.42 | 2024 | Voquezna |
| Lundbeck LLC | $70.21 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $66.75 | 2021-2024 | Glassia |
| Glaxosmithkline, LLC. | $66.23 | 2021-2023 | Nucala |
| Genzyme Corporation | $61.44 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.30 | 2022-2025 | Caplyta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $47.23 | 2025 | Ohtuvayre |
| Eisai INC. | $44.43 | 2021-2022 | |
| Insulet Corporation | $41.20 | 2025 | Omnipod |
| Dexcom, INC. | $39.45 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $35.70 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $33.17 | 2025 | Gardasil 9, Capvaxive, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.90 | 2024-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $29.90 | 2023 | Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $28.14 | 2022 | |
| Abbott Laboratories | $24.18 | 2021 | |
| Grifols USA, LLC | $18.71 | 2025 | Prolastin-C Liquid |
| Electromed, INC. | $13.51 | 2025 | Smartvest |
| Pfizer INC. | $13.38 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Bruno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.